AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: EUCRISA (Pfizer) (eucrisa.com)
EUCRISA is a high-substance pharmaceutical site that suffers from technical neglect and template fatigue. While the clinical and financial claims are specific and well-documented, the null schema and ‘corona msg’ artifacts suggest a brand operating on autopilot. It is low on marketing bullshit but moderately high on technical ‘ghost-brand’ indicators.
First, implement comprehensive Drug and Organization schema to link the product to Pfizer’s digital authority and verify regulatory status. Second, replace the ‘corona msg’ and ‘Footer Main menu’ [H2] tags with descriptive, keyword-rich headings that improve information architecture. Third, include direct citations or outbound links to the peer-reviewed studies supporting the PDE4 target and the 2016 clinical trials. Finally, update the site’s technical structure to eliminate the trust_theatre_flag by either linking reviews to a third-party validator or removing the static review count.
The information density is high for a pharmaceutical product site, featuring specific technical markers like ‘crisaborole 2%’ and the ‘PDE4 enzyme.’ While it uses some marketing-heavy headings like ‘EUCRISA works above and below the skin’s surface,’ the body text provides concrete details including FDA approval dates (2016) and specific clinical trial milestones (Day 29 results). However, substance is slightly diluted by technical artifacts in the headings, such as the repeated ‘corona msg’ [H2] and ‘Footer Main menu’ [H2], which offer zero information value to the user.
A validator checks markup; an AI audit checks comprehension. Start your free one page AI interpretation to see how your structured data is actually interpreted by LLMs.
The site maintains high alignment between its primary signal (eczema treatment and savings) and the sub-page content. The homepage H1 promise of ‘pay as little as $10’ is directly supported by the Patient Access sub-page with granular details: ‘$970 per tube’ limits and specific eligibility for commercial insurance. There is minimal drift, though the ‘Learn More’ paths for the mechanism of action lead to a significant hedge: ‘The specific way EUCRISA works is not well defined,’ which is a refreshingly low-BS admission for the industry.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The site triggers trust theatre flags due to a review_count of 1 across all pages with a proof_links_count of 0 in the structured data. This suggests a static testimonial or a ‘rating’ element that is not tied to a verifiable third-party platform. While the site cites ‘clinical trials’ and ‘full Prescribing Information,’ the absence of direct outbound links to ClinicalTrials.gov or peer-reviewed citations in the crawled text creates a closed-loop authority environment.
Proof density is moderate-to-high for the consumer-facing web, with specific mention of FDA approval years and exact savings figures ($10, $970, $3,880). The ratio of verifiable evidence to fluff is favorable, though the ‘proof_links_count: 0’ indicates that the evidence is stated rather than externally validated via linked documentation in the metadata. The most substantial proof point is the specificity of the ‘commercial insurance’ restrictions on the savings card.
To see how the methodology translates into real diagnostic output, review a full executive level analysis applied to a global fashion retailer. View the Mango Executive SEO Strategy for a concrete example of how structural gaps, semantic weaknesses, and conversion friction are surfaced in practice.
The site uses standard pharmaceutical template fingerprints including ‘Patient Resources’ and ‘Important Safety Information.’ The value proposition is somewhat unique due to the ‘100% steroid-free’ claim, which is a specific differentiator in the eczema market. However, generic value prop cliches like ‘We’re here to help!’ and the presence of boilerplate footer elements contribute to a moderate commodity score.
There is a significant technical authority gap as evidenced by the ‘schema_json: null’ status across all pages; a major pharma brand should leverage Drug or Organization schema to ground its expertise. Furthermore, while the site references ‘proprietary’ vehicles and ‘Support Representatives,’ no specific medical experts, researchers, or dermatology KOLs are named or linked to professional footprints. Technical credibility is hampered by the ‘corona msg’ H2 tags, indicating a lack of recent maintenance or poor CMS hygiene.
The performance claims are generally well-tethered to clinical evidence, specifically citing a 29-day trial period and showing ‘Before and After’ photos. The disconnect is minor but present in the ‘above and below’ claim, which is immediately followed by a disclaimer that the mechanism of action is ‘not well defined.’ This creates a ‘Signal vs. Substance’ gap where the marketing metaphor is stronger than the scientific proof provided.
Medical Devices, Pharma & Biotech BS: EUCRISA (Pfizer) (eucrisa.com)
The content perfectly matches the Pharma & Biotech category, specifically focusing on a prescription topical treatment (crisaborole) for atopic dermatitis. It adheres to pharmaceutical regulatory norms by including extensive ‘Important Safety Information’ (ISI) and specific ‘Indication’ blocks.
Your site's meaning is determined by its graph, not its menus. Review the Internal Linking Architecture Framework to see how AI interprets nodes, edges, and authority flow inside your domain.
“The score of 38 is driven primarily by technical authority gaps (null schema) and trust theatre flags (unverified reviews). While the content substance is strong (lowering the score), the presence of template artifacts and the lack of external proof paths prevent it from reaching a 'Minimal BS' rating. The 2026 temporal anchor makes the 2016 approval date appear 'stale,' further contributing to the technical neglect penalty.”